Phergain study
WebFeb 10, 2024 · The PHERGain II study's goal is to find an effective therapeutic strategy that can reduce the use of chemotherapy and improve the quality of life of patients without … WebJul 12, 2024 · PARP inhibitors (PARPi), olaparib and talazoparib, are indicated in patients with HER2-negative advanced breast cancer with germline BRCA1/2 mutations. Preclinical data have demonstrated an interaction between DNA damage induced by PARPi and the immune system.
Phergain study
Did you know?
WebOct 27, 2024 · The PHERGain study is still ongoing and results on long-term survival are expected to be released in 2024. Clinical Trial Registration: NCT03161353 … WebMay 29, 2024 · PHERGAIN In another trial, researchers showed that early evaluation of metabolic response using 18 F-FDG PET/CT could help identify patients who will develop a pCR to dual HER2 blockade alone, potentially …
WebMay 18, 2024 · PHERGain was a strategy-based study with a unique design. Previous trials of de-escalation strategies in HER2-positive, early-stage breast cancer have highlighted the importance of establishing innovative clinical designs, together with optimal selection of … WebThe PHERGain trial had two groups, or arms, discussed at the 2024 ASCO Annual Meeting. In the control arm, the group that got standard treatment, 71 people got chemotherapy …
WebNational Center for Biotechnology Information WebThe PHERGain study is still ongoing and results on long-term survival are expected to be released in 2024. Clinical Trial Registration: NCT03161353 ( ClinicalTrials.gov ) View Download 21 Reads...
WebMay 19, 2024 · The study assess the early metabolic effects of neoadjuvant treatment with trastuzumab and pertuzumab (± endocrine therapy) on the primary tumor and axillary …
WebOct 27, 2024 · The study includes 376 women with a type of breast cancer called HER2-positive breast cancer that can be removed by surgery. In the study, researchers wanted … hot pot rice pudding recipeWebDec 13, 2024 · “To our knowledge, LINGain is the first study to assess the evolution of peripheral αβ and γδ T cells in the context of neoadjuvant chemotherapy-free regimen with trastuzumab and pertuzumab in HER2 [+] EBC patients. linear assumptionWebThe definitive assessment of pathological complete response was done at this primary analysis; follow-up to assess invasive disease-free survival is continuing, hence these … linear astrolabeWebMay 19, 2024 · (PHERGain) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. ClinicalTrials.gov Identifier: NCT03161353 Recruitment Status : Active, not recruiting hot pot richmond lansdowneWebJun 19, 2024 · The PHERGAIN study is evaluating the use of positron emission tomography (PET) imaging during neoadjuvant therapy to monitor tumor response in patients with HER2-positive breast cancer. In preliminary results, investigators reported that patients whose PET scan showed positive response to the treatment had pathological complete response. hot pot restaurant seattle waWebJun 10, 2024 · The addition of trastuzumab to chemotherapy dramatically improved the prognosis of early-stage human epidermal growth factor receptor 2 (HER2)–positive breast cancer. However, 15%-31% of patients still develop disease recurrence, on the basis of long-term follow-up of adjuvant pivotal trials. A better understanding of tumor biology has led … linear assumption regressionWebFeb 24, 2024 · PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer. The PHERGain II trial will investigate the treatment … linear atelectasis at the left base